What Primmune Therapeutics does

Primmune Therapeutics is a clinical-stage biotechnology company developing PRTX007, a novel, orally administered, systemically active small-molecule agonist of toll-like receptor 7 (TLR7). PRTX007 is designed as a prodrug that converts to active metabolite PRX034 and selectively activates plasmacytoid dendritic cells (pDCs) to generate Type I and Type III interferon-associated innate immune programs while deliberately minimizing engagement of NF-κB-driven pro-inflammatory pathways that have historically limited systemic TLR7/8 agonists. The company has coined the term "TherAjuvant" to describe PRTX007's combined therapeutic and adjuvant mechanism, intended to coordinate innate and adaptive immunity while preserving lymph node function.

The company's clinical strategy spans oncology (solid tumors, neoadjuvant melanoma in combination with anti-PD-1 therapy) and viral diseases (RSV, COVID-19, HPV-driven high-grade squamous intraepithelial lesions, Lassa Fever, and hepatitis B/D). As of early 2026, PRTX007 had been administered to 119 healthy volunteers across two Phase 1 studies (PRTX007-001 and PRTX007-002) with a favorable safety profile and no serious adverse events, and the company had initiated a Phase 2 neoadjuvant study in Stage III resectable melanoma in Australia under Novotech. The company is led by co-founders Charlie McDermott (President & CEO), James Appleman (SVP R&D/CSO), Paulo Rangel (CBO), and Stephen Webber (VP Medicinal Chemistry), with a recent CMO appointment of Andrew Sharabi, MD, PhD.

Primmune is pre-revenue with no disclosed pricing or commercial products. The business model anticipates revenue through licensing/royalty arrangements, partnership deals, or direct pharmaceutical sales following regulatory approval. The company is venture-backed, having raised approximately $38.4M in equity ($7M seed, $31.4M Series A, $23.3M Series B) plus a $22.5M non-dilutive contract from the Defense Threat Reduction Agency (DTRA) for Lassa Fever development. Backers include CAM Capital, Polaris Partners, Bioqube Ventures, Oberland Capital, and Samsara Biocapital. Operational footprint spans Carlsbad, CA (headquarters), San Diego (JLABS), Belgium (European subsidiary), and Australia (clinical operations).

Name

Primmune Therapeutics

Legal name

Primmune Therapeutics, Inc.

Website

https://primmunerx.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Primmune Therapeutics is a clinical-stage biotechnology company developing PRTX007, an orally administered TLR7 agonist immunotherapy that activates plasmacytoid dendritic cells to generate interferon-driven innate immune responses for oncology and viral disease indications.

Ownership category

akta.pro rank

Product category

Immuno-oncology biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Dendritic Cell & Other APC-based Therapies (HLAAABAF)

akta.pro secondary industry

Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)

Keywords

• Immuno-oncology therapeutics
• TLR7 agonist immunotherapy
• Small-molecule cancer drugs
• Antiviral immunotherapy
• Clinical-stage biotechnology

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Drug Development and Commercialization: Primmune is a clinical-stage biotech with no current revenue. The company is developing PRTX007 through clinical trials for cancer and viral disease indications. Revenue will be generated upon regulatory approval and commercialization, either through direct sales, partnerships, or licensing agreements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Primmune Therapeutics is developing PRTX007, an orally administered, systemically active small-molecule toll-like receptor 7 (TLR7) agonist designed to activate plasmacytoid dendritic cells (pDCs) and selectively trigger interferon-associated innate immune programs. The company is advancing PRTX007 through Phase 1 and Phase 2 clinical trials for oncology indications (including combination with anti-PD-1 therapy in Stage III resectable melanoma), viral diseases (Lassa fever, RSV, COVID-19, hepatitis B and D), and pre-cancerous HPV-driven lesions.

Product overview

Primmune Therapeutics is a clinical-stage biotechnology company developing a single lead product candidate, PRTX007, as a novel orally-administered TLR7 agonist immunotherapy. The company was founded to develop systemic cancer immunotherapies that activate both innate and adaptive immunity through targeted activation of plasmacytoid dendritic cells. PRTX007 represents the company's entire clinical portfolio and is being advanced for oncology applications (solid tumors, melanoma in combination with anti-PD-1 therapy) and antiviral applications (Lassa fever via DTRA contract). The company uses the term TherAjuvants™ to describe its approach combining therapeutic and adjuvant mechanisms in a single molecule.

Differentiator

Problem solved

Functional benefit

Brands

• TherAjuvant: A proprietary term coined by Primmune Therapeutics to reference its lead candidate PRTX007, describing its combination of therapeutic and adjuvant mechanisms of action. PRTX007 is designed to provide immediate benefit through controlled stimulation of the innate immune response while also potentiating long-term effective innate and adaptive immune responses.

Products and services

• PRTX007 PRTX007 is a novel, orally administered, systemically active small-molecule toll-like receptor 7 (TLR7) agonist immunotherapy designed in-house to activate plasmacytoid dendritic cells (pDCs) and selectively drive interferon-associated innate immune programs while minimizing NF-κB-driven pro-inflammatory pathways. It is being developed for solid tumors (including Stage III resectable melanoma in combination with anti-PD-1 therapy), viral diseases (Lassa fever under a DTRA contract, RSV, COVID-19, hepatitis B and D), and HPV-driven high-grade squamous intra-epithelial lesions (HSIL). PRTX007 has been administered to 119 healthy volunteers across two Phase 1 studies demonstrating favorable safety and consistent systemic immune engagement without serious adverse events.

Quantifiable outcome

• 119 healthy volunteers treated with PRTX007 across two Phase 1 studies demonstrating favorable safety profile with no serious adverse events observed

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• NovotechmajorImplementation/ SI/ Consulting Partner · 26 January 2026Novotech serves as the clinical research organization (CRO) for Study PRTX007-003, a Phase 2 neoadjuvant efficacy study in Stage III resectable melanoma being conducted entirely in Australia.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Nektar Therapeutics: Nektar developed NKTR-262, a TLR7/8 agonist conjugated polymer for combination cancer immunotherapy. Directly comparable mechanism (systemic TLR7/8 agonism) and oncology indication focus, though at a later clinical stage.
• Bolt Biotherapeutics: Bolt is developing TLR7/8 agonist-based immune-stimulating antibody conjugates (ISACs) for cancer. Similar innate immune activation mechanism via TLR engagement and oncology focus makes it a direct clinical-stage competitor in the TLR agonist immunotherapy space.
• Ventyx Biosciences: Ventyx has developed TLR7/8 agonists as part of its immunology pipeline. Direct comparable in TLR-targeted small-molecule drug development for immune-mediated diseases, though with somewhat different therapeutic positioning.

Broad incumbents

• Dynavax Technologies: Dynavax commercializes HEPLISAV-B, a TLR9 agonist vaccine adjuvant for hepatitis B. Comparable TLR-targeted immunotherapy platform with approved product, but focuses on vaccine adjuvants rather than direct anti-tumor immune activation.
• Regeneron (Checkmate Pharmaceuticals): Regeneron acquired Checkmate Pharmaceuticals, which developed CMP-CPS-001 (a TLR9 agonist for cancer). Comparable TLR-agonist cancer immunotherapy approach; Regeneron represents the broad incumbent acquirer in this category.

Emerging players

• eFFECTOR Therapeutics: Primmune co-founders James Appleman and Stephen Webber previously co-founded eFFECTOR, which develops translation-regulating cancer immunotherapies. Overlapping scientific DNA and shared investor relationships make it thematically comparable in cancer immunotherapy drug development.
• Asher Biotherapeutics: Asher develops cis-targeting immunotherapies designed to selectively activate immune responses, including TLR-pathway approaches. Comparable in being an early-stage company pursuing engineered immune activation with reduced off-target inflammation.
• Sotio Biotech: Sotio develops immunotherapies including immune agonists for solid tumors. Comparable in pursuing innate immune activation strategies for cancer with clinical-stage programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/PrimmuneRx
• Facebookfacebook.com/Primmune-Therapeutics-1503521086370094
• LinkedInlinkedin.com/company/primmune-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Primmune Therapeutics